title: Technical note: Effects of rumen passage on fluoxetine bioavailability in serum and effects of fluoxetine on serum prolactin concentration and demeanor in ewes.
abstract: Sheep are becoming increasingly important in medical research. The objective of the present study was to identify changes in bioactivity of fluoxetine during ruminal passage in ewes, and to examine the effects of fluoxetine administration on demeanor and serum prolactin concentration. Twelve mature ewes were administered saline (control), daily oral fluoxetine (40 mg), or alternate-day oral fluoxetine for 10 d. Four additional ewes were fitted with rumen cannulas and administered daily fluoxetine by abomasal deposition. Serum samples were collected daily for 15 d. Serum fluoxetine concentrations (ELISA) were greater (P < 0.001) in ewes in all fluoxetine treatments compared with controls on d 2. Serum fluoxetine concentrations in ewes receiving daily abomasal dosages were greater (P < 0.007) than those in controls on d 2 to 12 and were greater than those in ewes receiving daily or alternate-day oral fluoxetine on d 3 to 12. Serum prolactin concentration (RIA) did not differ (P = 0.137) among treatments and was only weakly correlated with serum fluoxetine concentration (r = 0.20, P = 0.041), and regression analysis revealed that very little variation in serum prolactin concentration was due to serum fluoxetine concentration (R(2) = 0.04, P = 0.082). Demeanor ratings on d 1 to 12 remained at normal in all treatment groups (P > 0.362). However, in ewes that had received an abomasal dosage of fluoxetine, demeanor scores decreased (P < 0.029) on d 13 and 14 before returning to normal on d 15 (P = 0.397). This study indicates that mature ewes may provide a suitable model for the study of fluoxetine, but that a larger oral dosage may be required relative to the human dosage to overcome partial loss of bioactivity during ruminal passage.
authors.affiliation: Department of Animal and Range Sciences, New Mexico State University, Las Cruces, 88003, USA. dty4888@yahoo.com
authors.forename: D T
authors.initials: DT
authors.lastname: Yates
authors.forename: G L
authors.initials: GL
authors.lastname: Strosser
authors.forename: P L
authors.initials: PL
authors.lastname: Black
authors.forename: R A
authors.initials: RA
authors.lastname: Halalsheh
authors.forename: L M
authors.initials: LM
authors.lastname: Lankford
authors.forename: L L
authors.initials: LL
authors.lastname: Hernandez
authors.forename: C A
authors.initials: CA
authors.lastname: Löest
authors.forename: T T
authors.initials: TT
authors.lastname: Ross
mesh_terms: D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects*; D001682:Biological Availability; D004333:Drug Administration Routes; D004334:Drug Administration Schedule; D005473:Fluoxetine / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics* / Q000494:pharmacology*; D005769:Gastrointestinal Motility; D011388:Prolactin / Q000097:blood*; D012417:Rumen / Q000502:physiology*; D017367:Selective Serotonin Reuptake Inhibitors / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics / Q000494:pharmacology; D012756:Sheep
chemical_list: D005473:Fluoxetine; D011388:Prolactin; D017367:Selective Serotonin Reuptake Inhibitors